New Zealand markets closed

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.50-0.19 (-2.84%)
At close: 04:00PM EST
6.50 0.00 (0.00%)
Pre-market: 04:03AM EST

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive
Norwood, MA 02062
United States
617 963 0100

Full-time employees33

Key executives

NameTitlePayExercisedYear born
Dr. Yuval Cohen Ph.D.CEO & Director890.67kN/A1975
Mr. Sean F. Moran CPA, M.B.A.Chief Financial Officer579.05kN/A1958
Dr. Rachael Brake Ph.D.Chief Scientific Officer552.22kN/A1972
Ted JenkinsSenior Director of Investor Relations & Corporate CommunicationsN/AN/AN/A
Ms. Lindsey SmithHead of Corporate Communications & Patient AdvocacyN/AN/AN/A
Ms. Christina BertschHead of Human ResourcesN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corporate governance

Corbus Pharmaceuticals Holdings, Inc.’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.